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Abstract
Purpose Childhood cancer survivors are at increased risk of developing subsequent malignant neoplasms (SMNs). We com-
pared survival and clinical characteristics of survivors with SMNs (sarcoma, breast cancer, or melanoma) and a population-
based sample of similar first malignant neoplasm (FMN) patients.
Methods We assembled three case series of solid SMNs observed in a cohort of 5-year Dutch childhood cancer survivors 
diagnosed 1963–2001 and followed until 2014: sarcoma (n = 45), female breast cancer (n = 41), and melanoma (n = 17). Each 
SMN patient was sex-, age-, and calendar year-matched to 10 FMN patients in the population-based Netherlands Cancer 
Registry. We compared clinical and histopathological characteristics by Fisher’s exact tests and survival by multivariable 
Cox regression and competing risk regression analyses.
Results Among sarcoma-SMN patients, overall survival [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.23–2.87] 
and sarcoma-specific mortality (HR 1.91, 95% CI 1.16–3.13) were significantly worse compared to sarcoma-FMN patients 
(foremost for soft-tissue sarcoma), with 15-year survival rates of 30.8% and 61.6%, respectively. Overall survival did not 
significantly differ for breast-SMN versus breast-FMN patients (HR 1.14, 95% CI 0.54–2.37), nor for melanoma-SMN versus 
melanoma-FMN patients (HR 0.71, 95% CI 0.10–5.00). No significant differences in tumor characteristics were observed 
between breast-SMN and breast-FMN patients. Breast-SMN patients were treated more often with mastectomy without 
radiotherapy/chemotherapy compared to breast-FMN patients (17.1% vs. 5.6%).
Conclusions Survival of sarcoma-SMN patients is worse than sarcoma-FMN patients. Although survival and tumor charac-
teristics appear similar for breast-SMN and breast-FMN patients, treatment differs; breast-SMN patients less often receive 
breast-conserving therapy. Larger studies are necessary to substantiate these exploratory findings.
Keywords Childhood cancer survivors · Subsequent malignant neoplasm · Survival · Epidemiology · Long-term 
complications
Introduction
Survivors of childhood cancer are at increased risk of devel-
oping long-term health problems even decades after treat-
ment [1–4]. Subsequent malignant neoplasms (SMNs) are 
among the most serious adverse conditions that childhood 
cancer survivors may develop and represent a major cause 
of morbidity and mortality [5–9].
Several studies have addressed differences in prognostic, 
clinical, and/or histopathological characteristics of specific 
types of solid SMNs after childhood, adolescent, and young 
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adult cancers and comparable first malignant neoplasms 
(FMNs) in the general population [10–19]. Since the major-
ity of these type of studies focused on breast-SMN, most 
were conducted in Hodgkin lymphoma or other adolescent 
and young adult (AYA) cancer survivors. Only few studies 
have specifically focused on young cancer survivors [12, 14, 
17] and few have compared cause-specific survival between 
patients with specific types of SMNs following cancer at a 
young age and comparable FMN patients [14, 16].
Therefore, we examined clinical characteristics, overall 
survival, and cause-specific survival of patients in the Dutch 
Childhood Cancer Oncology Group—Long-Term Effects 
After Childhood Cancer (DCOG-LATER) cohort who devel-
oped SMNs of sarcoma, breast, or melanoma and compared 
those outcomes with matched patients having similar FMNs 
in the general population, based on the Netherlands Cancer 
Registry (NCR). We hypothesized that survival of SMNs 
may be different from survival of FMNs for several reasons: 
earlier detection due to surveillance efforts among survivors 
(favorable), variability of tumor characteristics due to dif-
ferent pathogenesis (favorable or unfavorable), limited treat-
ment options due to previous childhood cancer treatment 
(unfavorable), and a higher frequency of other potentially 
lethal long-term chronic health conditions (unfavorable).
Methods
Subsequent solid malignant neoplasms 
in the DCOG‑LATER cohort
The DCOG-LATER cohort includes 6,165 five-year child-
hood cancer survivors diagnosed before the age of 18 years 
in one of the seven Dutch pediatric oncology and stem cell 
transplant centers between 1 January 1963 and 31 Decem-
ber 2001. Detailed information on childhood cancer diag-
nosis and treatment was collected and incident SMNs were 
obtained via various methods, as previously described [8]. 
This particular study included cohort members with SMNs 
(referred to as SMN patients hereafter) diagnosed from 1989 
through 2014 that were verified by the NCR (population-
based ≥ 1989) [20]. We designed three case series of most 
prevalent invasive subsequent solid SMNs observed in the 
DCOG-LATER cohort: sarcoma, female breast cancer, and 
melanoma. Eligible morphology/topography codes are pre-
sented in Supplementary Table 1. In an earlier report on the 
current cohort, sarcoma, female breast cancer, and mela-
noma were shown to represent 20%, 20%, and 4%, respec-
tively, of the total number of solid SMNs [8]. To avoid mis-
classification and bias, we excluded patients for whom the 
respective SMN of inclusion was a third tumor preceded by 
an intervening second malignancy treated with radiotherapy 
and/or chemotherapy.
Population‑based first malignant neoplasms (FMN)
Each of the SMN patients in the three case series (sarcoma, 
female breast cancer, and melanoma) from the DCOG-
LATER cohort was matched to 10 comparison patients with 
FMNs from the population-based NCR (referred to as FMN 
patients hereafter), based on sex, age at cancer diagnosis, 
calendar year of cancer diagnosis ± 3 years, and for sarcomas 
also on primary site (bone/soft tissue). When > 10 compari-
son patients fulfilled these criteria, the 10 patients closest 
to incidence date of the corresponding case were selected. 
When less than the 10 comparison FMN patients from the 
cancer registry fulfilled these criteria for a specific index 
SMN patient, the matching criterion for age was widened 
until 10 eligible comparison FMN patients were identified. 
That is, the FMN comparison group was supplemented with 
cancer patients closest in age at their respective FMN cancer 
diagnosis to the index SMN case diagnosis, but within the 
same diagnosis calendar year defined by the index SMN 
case. Sampled comparison patients were excluded from 
serving as FMN patients if they had a history of cancer, 
with the exception of basal cell carcinoma.
Data on prognostic, clinical, and histopathological 
characteristics
The following SMN/FMN characteristics were obtained 
from the NCR: morphology, stage, grade, treatment (for 
all three cancer sites yes/no indicators for surgery, chemo-
therapy, and radiotherapy and for breast cancer additionally 
yes/no indicators for mastectomy, breast-conserving sur-
gery, and hormonal therapy), and vital status. For patients 
with breast cancer, information on receptor status was also 
retrieved. No genetic data were available. Patients were fol-
lowed until date of death, date of emigration, or through 
12/31/2016, whichever occurred first. Coded cause of death 
information for deceased SMN/FMN patients was obtained 
by linkage with Statistics Netherlands. We categorized cause 
of death into cancer of interest-related deaths and death due 
to other causes. Data collection for the study was exempted 
from review by the Institutional Review Boards of all par-
ticipating centers and all data were processed and analyzed 
anonymously.
Statistical analyses
We compared clinical and histopathological characteristics 
for SMN and FMN patients by Fisher’s exact tests. Overall 
survival was calculated using Kaplan–Meier methods and 
represented by Kaplan–Meier curves. For cause-specific 
mortality, cumulative incidences functions (probability of 
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death due to the specific cause) were estimated. When evalu-
ating cancer of interest-related deaths, deaths due to other 
causes were treated as a competing risk and vice versa. We 
used Cox proportional hazard regression analyses to test 
differences in overall survival between the SMN and FMN 
groups in univariable models with patient group (SMN vs. 
FMN) as an independent variable and in multivariable mod-
els with additional factors hypothesized to influence a dif-
ference in survival between the SMN and FMN groups. For 
sarcoma, morphology was one of the factors we adjusted for 
in the analyses. For any sarcoma, we grouped morphology 
into three groups based on similarity in survival estimates 
reported in literature: (1) osteosarcoma/rhabdomyosarcoma; 
(2) chondrosarcoma; (3) other or unspecified. Proportional-
ity of hazards for each variable was evaluated by adding 
interaction terms with follow-up time. Fine and Gray com-
peting risk models were used to test differences between 
SMN and FMN patients with respect to mortality due to the 
cancer of interest and mortality from other causes [21]. All 
analyses were performed with Stata 14 software (StataCorp. 
2015. Stata Statistical Software: Release 14. College Sta-
tion, TX: StataCorp LP).
Results
Sarcoma—comparison of clinical 
and histopathological characteristics
Of 46 eligible patients with subsequent sarcoma (sarcoma-
SMN) after childhood cancer, one patient was excluded 
because of a SMN diagnosis (acute lymphoblastic leuke-
mia (ALL); treatment with radiotherapy and chemotherapy) 
prior to developing a sarcoma as third malignancy. We also 
excluded one comparison patient in the first primary sar-
coma (sarcoma-FMN) group, who was erroneously selected 
for inclusion, despite a history of a prior cancer. In total, 
we included 45 sarcoma-SMN patients and 449 sarcoma-
FMN patients. Among sarcoma-SMN patients, 30.4% also 
had a sarcoma as childhood cancer diagnosis, 8.7% had a 
retinoblastoma as childhood cancer diagnosis, and 60.9% 
had previous radiotherapy treatment to the sarcoma-SMN 
region (Supplementary Table 2).
Several differences were observed in the morphology 
of sarcoma-SMNs and sarcoma-FMNs. Twenty-seven per-
cent of sarcoma-SMN patients had osteosarcoma, versus 
12.9% of sarcoma-FMN patients (Table 1) (p = 0.022, not 
shown). In contrast, none of the sarcoma-SMN patients 
had Ewing sarcoma, while this was the morphology of 
13.1% of sarcoma-FMN patients. Fibrosarcoma was much 
less common among sarcoma-SMN patients (2.2%) than 
among sarcoma-FMN patients (16.5%) (p = 0.008, not 
shown), with dermatofibrosarcomas protuberans being the 
largest contributor of fibrosarcomas among FMN patients 
(62 cases, 13.8%). Remarkably, no dermatofibrosarco-
mas protuberans occurred among sarcoma-SMN patients. 
Among the minority with a known tumor grade (34.4%), 
sarcoma-SMN patients were more likely to have a high 
tumor grade than sarcoma-FMN patients (SMN 60.0% vs. 
FMN 26.0% poor/high grade and SMN 10.0% vs. FMN 
2.0% undifferentiated/anaplastic grade for sarcoma-SMN 
and sarcoma-FMN patients, respectively; p = 0.002). We 
did not observe significant differences in stage distribution 
or treatments received.
Sarcoma—overall and cause‑specific survival
Median follow-up time was 3.6 years (max 34.0 years) for 
sarcoma-SMN patients and 7.5 years (max 28.0 years) for 
sarcoma-FMN patients. At the end of follow-up, 62.2% of 
sarcoma-SMN patients were deceased compared to 33.2% 
of sarcoma-FMN patients (Table 1). Because dermatofibro-
sarcoma protuberans behaves in many respects as a benign 
tumor and has very high survival rates [22], we excluded 
those patients (n = 62, all sarcoma-FMN patients) from all 
survival analyses. Furthermore, we excluded Ewing sarcoma 
(n = 59, all sarcoma-FMN patients) and Kaposi sarcoma 
(n = 19, 18 sarcoma-FMN patients and 1 sarcoma-SMN 
patient) from all survival analyses, because those sarcoma 
types are rare to occur as SMN. Survival rates after 5, 10, 
and 15 years were 44.9%, 38.5%, and 30.8%, respectively, 
among sarcoma-SMN patients, considerably lower than 
those among sarcoma-FMN patients with 67.4%, 63.1%, 
and 61.6%, respectively (Table 2, Fig. 1a). Overall survival 
was significantly worse among sarcoma-SMN patients (mul-
tivariable HR 1.88; 95% CI 1.28–2.87) (Table 3, Fig. 1). 
Sarcoma-specific mortality was also significantly higher in 
sarcoma-SMN patients compared to sarcoma-FMN patients 
(15-year mortality 66.0% vs. 34.5% and multivariable HR 
1.91; 95% CI 1.16–3.13, Tables 2 and 3). Mortality due to 
other causes after 5, 10, and 15 years was very low in all 
groups (< 3%).
Stratified by type of sarcoma, survival differences 
between SMN and FMN patients seemed to be greater 
for soft-tissue sarcoma (multivariable HR 2.31; 95% CI 
1.37–3.89) than for bone sarcoma (multivariable HR 1.21; 
95% CI 0.57–2.53) (Supplementary Table 3, Supplementary 
Fig. 1). In analyses per specific sarcoma morphology type, 
we found no difference in survival between osteosarcoma-
SMN and FMN patients (multivariable HR 1.02; 95% CI 
0.45–2.34), but we found a statistically significant difference 
between synovial sarcoma SMN and FMN patients (mul-
tivariable HR 7.82; 95% CI 1.41–43.35) (not shown). For 
other specific sarcoma morphology types, numbers were too 
small to make meaningful comparisons.
912 Cancer Causes & Control (2019) 30:909–922
1 3
Table 1  Characteristics of patients with sarcomas and melanomas as a subsequent malignant neoplasm (SMN) and matched patients with sarco-
mas and melanomas as a first malignant neoplasm (FMN)
Sarcoma p value Melanoma p value
DCOG-LATER 
cohort SMN
(n = 45)
Cancer registry 
FMN
(n = 449)a
DCOG-LATER 
cohort SMN
(n = 17)
Cancer registry 
FMN
(n = 170)
N % N % N % N %
Age at  diagnosisb 0.924 1.000
 < 30 years 35 77.8 335 74.6 6 35.3 60 35.3
 30–39 years 8 17.8 83 18.5 6 35.3 60 35.3
 40 + years 2 4.4 31 6.9 5 29.4 50 29.4
Sexb 1.000 1.000
 Male 25 55.6 249 55.5 6 35.3 60 35.3
 Female 20 44.4 200 44.5 11 64.7 110 64.7
Incidence  yearb 0.909 1.000
 1989–1999 12 26.7 129 28.7 3 17.7 29 17.1
 2000–2009 25 55.6 249 55.5 8 47.1 81 47.7
 2010–2014 8 17.8 71 15.8 6 35.3 60 35.3
Morphology sarcoma NE
 Osteosarcoma 12 26.7 58 12.9
 Chondrosarcoma 4 8.9 57 12.7
 Ewing sarcoma 0 0.0 59 13.1
 Rhabdomyosarcoma 3 6.7 23 5.1
 Leiomyosarcoma 4 8.9 22 4.9
 Fibrosarcoma 1 2.2 74 16.5
 Malignant fibrous histiocytoma 2 4.4 12 2.7
 Malignant peripheral nerve sheath tumor 3 6.7 23 5.1
 Liposarcoma 3 6.7 19 4.2
 Synovial sarcoma 3 6.7 24 5.4
 Kaposi sarcoma 1 2.2 18 4.0
 Other or unspecified bone 1 2.2 19 4.2
 Other or unspecified soft  tissued 8 17.8 41 9.1
Morphology melanoma 0.335
 Nodular 1 5.9 20 11.8
 Superficial spreading 15 88.2 117 68.8
 Other or unspecified 1 5.9 33 19.4
Stagee 0.977 1.000
 I 12 57.1 106 50.2 13 76.5 120 73.6
 II 5 23.8 53 25.1 3 17.7 28 17.2
 III 0 0.0 7 3.3 1 5.9 15 9.2
 IV 4 19.1 45 21.3 0 0.0 0 0.0
 Unknown 24 238 0 7
Gradee 0.002 NE
 Well/low grade 4 20.0 79 52.7 0 0.0 0 0.0
 Moderate/intermediate 2 10.0 29 19.3 0 0.0 0 0.0
 Poor/high 12 60.0 39 26.0 0 0.0 0 0.0
 Undifferentiated/anaplastic 2 10.0 3 2.0 0 0.0 0 0.0
 Unknown 25 299 17 170
Surgery 0.256 0.382
 No 13 28.9 95 21.2 1 5.9 4 2.4
 Yes 32 71.1 354 78.8 16 94.1 166 97.7
Radiotherapy 0.716 1.000
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Breast cancer—comparison of clinical 
and histopathological characteristics
Of 42 eligible patients with subsequent female breast can-
cer (breast-SMN) after childhood cancer, one was excluded 
because of radiotherapy treatment for an intervening men-
ingioma prior to breast cancer diagnosis. We included 41 
breast-SMN patients and 410 matched first primary female 
breast cancer (breast-FMN) patients. Of all breast-SMN 
cases, 17.1% occurred after a Hodgkin lymphoma diagno-
sis and 40.0% after a sarcoma diagnosis (Supplementary 
Table 2). Almost one-third of the breast-SMN patients 
(31.7%) had no prior radiotherapy and also nearly one-
third (31.7%) had prior radiotherapy to the region where 
the breast cancer developed (26.8% with chest radiotherapy 
and 4.9% with total body irradiation). More than half of the 
breast-SMN patients (53.7%) had prior anthracycline treat-
ment (Supplementary Table 2).
Table 4 shows tumor and breast cancer treatment char-
acteristics of the breast-SMN and breast-FMN patients. 
The proportion of patients with infiltrating ductal carci-
noma was the same in the breast-SMN (87.8%) and FMN 
(87.3%) groups, as were the distributions of stage and 
grade. Patients in the breast-SMN group were more likely 
to have been treated without surgery (SMN 9.8% vs. FMN 
3.2%), but markedly more likely to have received mas-
tectomy (SMN 63.4% vs. FMN 49.3%) than breast-FMN 
patients (p = 0.024). Breast-SMN patients were less likely, 
however, to have received radiotherapy (SMN 51.2% vs. 
FMN 71.7%, p = 0.011) and chemotherapy (SMN 58.5% 
vs. FMN 76.3%, p = 0.011) compared to breast-FMN 
patients. No significant differences were observed in hor-
mone receptor status single or combined, i.e., triple nega-
tive, and receipt of hormonal therapy between breast-SMN 
and breast-FMN patients. When evaluating combinations 
of treatments, a higher proportion of breast-SMN patients 
received mastectomy without RT or CT compared to 
breast-FMN patients (SMN 17.1% vs. FMN 5.6%). Also, a 
lower proportion of breast-SMN patients was treated with 
breast-conserving surgery with radiotherapy and/or chem-
otherapy (SMN 26.8% vs. FMN 46.6%). In both groups, 
the majority of patients who did not have surgery for breast 
cancer had stage IV disease (SMN 75.0% vs. FMN 84.6%). 
For at least three of seven (42.9%) breast-SMN patients 
with mastectomy without radiotherapy or chemotherapy 
(± hormonal therapy), there was an indication that prior 
childhood cancer treatment limited breast cancer treatment 
options. One breast-SMN patient received a mastectomy 
CT chemotherapy, FMN first malignant neoplasm, NE not estimable, RT radiotherapy, SMN subsequent malignant neoplasm
a 1 control was excluded, because this patient appeared to have had a prior malignancy
b Matching factors
c Included 1 unspecified bone sarcoma among sarcoma-SMN patients
d Included 2 each with unspecified soft-tissue sarcoma and giant cell sarcoma, 1 each with spindle cell sarcoma, round cell sarcoma, hemangio-
sarcoma, and hemangiopericytoma among sarcoma-SMN patients
e Percentages and p values for stage and grade are based on subjects with known information only
Table 1  (continued)
Sarcoma p value Melanoma p value
DCOG-LATER 
cohort SMN
(n = 45)
Cancer registry 
FMN
(n = 449)a
DCOG-LATER 
cohort SMN
(n = 17)
Cancer registry 
FMN
(n = 170)
N % N % N % N %
 No 33 73.3 341 76.0 17 100 168 98.8
 Yes 12 26.7 108 24.1 0 0.0 2 1.2
Chemotherapy 0.632 NA
 No 26 57.8 277 61.7 17 100 170 100
 Yes 19 42.2 172 38.3 0 0.0 0 0.0
Treatment category 0.165 0.493
 No treatment 6 13.3 23 5.1 1 5.9 4 2.4
 Surgery only 16 35.6 199 44.3 16 94.1 164 96.5
 Surgery + RT and/or CT 16 35.6 155 34.5 0 0.0 2 1.2
 RT and/or CT only 7 15.6 72 16.0 0 0.0 0 0.0
Vital status at end of follow-up < 0.001 0.685
 Alive 17 37.8 300 66.8 15 88.2 153 90.0
 Deceased 28 62.2 149 33.2 2 11.8 17 10.0
914 Cancer Causes & Control (2019) 30:909–922
1 3
because adjuvant radiotherapy was impossible due to pre-
vious chest radiotherapy treatment for Hodgkin lymphoma 
and two breast-SMN patients had an indication for adju-
vant chemotherapy, but were not treated because the maxi-
mum cumulative anthracycline dose would be exceeded.
Breast cancer—overall and cause‑specific survival
Median fol low-up t ime was 6.3  years  (range 
0.5–20.3 years) for breast-SMN patients and 7.1 years 
(range 0.3–27.9 years) for breast-FMN patients. At end of 
Table 2  Overall survival and cause-specific mortality of subsequent malignant neoplasm and matched first malignant neoplasm cohorts
CI confidence interval, FMN first malignant neoplasm, SMN subsequent malignant neoplasm
a Patients with dermatofibrosarcoma protuberans (n = 62 FMN), Ewing sarcoma (n = 54 FMN), and Kaposi sarcoma (n = 18 FMN and n = 1 
SMN) were excluded
b Metastatic breast cancers (stage IV; n = 3 breast-SMN patients and n = 22 breast-FMN patients) and breast cancers with unknown stage (n = 1 
breast-SMN patients and n = 2 breast-FMN patients) were excluded
c 1 control was excluded, because this patient appeared to have had a prior malignancy
d Because of missing causes of death, the values do not always correspond with the overall survival numbers
e Mortality due to other causes was considered a competing risk
f Mortality due to the cancer of interest was considered a competing risk
Sarcomaa Breast  cancerb Melanoma
SMN (n = 45) FMN (n = 449)c SMN (n = 41) FMN (n = 410) SMN (n = 17) FMN (n = 170)
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
5-year overall survival 44.9 (29.9–58.9) 67.4 (61.8–72.3) 93.8 (77.4–98.4) 88.5 (84.7–91.4) 94.1 (65.0–99.2) 93.4 (88.4–96.3)
10-year overall survival 38.5 (23.7–53.2) 63.1 (57.3–68.3) 73.6 (52.0–86.6) 79.9 (74.8–84.1) 82.4 (42.6–95.7) 88.9 (82.3–93.2)
15-year overall survival 30.8 (16.5–46.3) 61.6 (55.6–67.1) 63.1 (34.9–81.8) 77.4 (71.5–82.2) 82.4 (42.6–95.7) 87.2 (79.5–92.2)
5-year  mortalityd
 Cancer of  intereste 51.6 (35.7–65.3) 30.8 (25.6–36.1) 6.2 (1.1–17.9) 10.8 (7.8–14.3) 0.0 5.5 (2.7–9.7)
 Other  causesf 2.4 (0.2–11.0) 0.7 (0.1–2.2) 0.0 0.0 0.0 0.6 (0.1–3.0)
10-year  mortalityd
 Cancer of  intereste 58.2 (41.2–71.8) 33.9 (28.5–39.4) 22.7 (9.0–40.0) 17.2 (13.2–21.7) 12.5 (0.7–42.3) 10.0 (5.6–15.8)
 Other  causesf 2.4 (0.2–11.0) 1.9 (0.7–4.2) 3.8 (0.3–16.1) 0.7 (0.1–3.6) 0.0 0.6 (0.1–3.0)
15-year  mortalityd
 Cancer of  intereste 66.0 (47.6–79.3) 34.5 (29.0–40.0) 33.2 (12.2–56.1) 19.8 (15.0–25.1) 12.5 (0.7–42.3) 10.0 (5.6–15.8)
 Other  causesf 2.4 (0.2–11.0) 1.9 (0.7–4.2) 3.8 (0.3–16.1) 0.7 (0.1–3.6) 0.0 2.3 (0.4–8.1)
Fig. 1  Overall survival of patients with a subsequent malignant neoplasm 
(SMN) and matched patients with a first malignant neoplasm (FMN) for 
sarcoma (a) and non-metastatic breast cancer (stage I–III) (b). Patients 
with dermatofibrosarcoma protuberans (n = 62 FMN), Ewing sarcoma 
(n = 54 FMN), and Kaposi sarcoma (n = 18 FMN and n = 1 SMN) were 
excluded in the sarcoma plot
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follow-up, 12 (29.3%) breast-SMN patients were deceased 
compared to 89 (21.7%) breast-FMN patients (Table 4). 
For non-metastatic breast cancer (stage I–III), overall 
survival rates after 5 and 15 years were 93.8% (95% CI 
77.4–98.4%) and 63.1% (95% CI 34.9–81.8%) among 
breast-SMN patients and 88.5% (95% CI 84.7–91.4%) and 
77.4% (95% CI 71.5–82.2%) among breast-FMN patients, 
respectively (Table 2, Fig. 1b). Fifteen-year survival rates 
among all patients with breast cancer (including meta-
static) were 47.6% (95% CI 21.9–69.5%) for breast-SMN 
and 73.2% (95% CI 67.3–78.1%) for breast-FMN patients. 
For non-metastatic breast cancer, breast cancer-specific 
mortality at 15-year was 33.2% (95% CI 12.2–56.1%) for 
breast-SMN patients and 19.8% (95% CI 15.0–25.1%) for 
breast-FMN patients (Table 2). Mortality due to other 
causes was very low (0–4%). Overall survival did not sig-
nificantly differ between breast-SMN patients and breast-
FMN patients (multivariable HR 1.14; 95% CI 0.54–2.37) 
(Table 5). Similar trends were observed for breast can-
cer-specific mortality (multivariable HR 1.09; 95% CI 
0.49–2.39).
Table 3  Regression analyses to ascertain the contribution of tumor and treatment characteristics between sarcoma as a subsequent malignant 
neoplasm (SMN) and sarcoma as a first malignant neoplasm (FMN) with respect to overall and cause-specific mortality
Patients with dermatofibrosarcoma protuberans (n = 62 FMN), Ewing sarcoma (n = 54 FMN), and Kaposi sarcoma (n = 18 FMN and n = 1 SMN) 
were excluded
CI confidence interval, FMN first malignant neoplasm, HR hazard ratio, SMN subsequent malignant neoplasm
a Cox proportional hazards regression analyses including 28 deaths among sarcoma-SMN patients and 114 deaths among sarcoma-FMN patients
b Competing risk regression analyses. When evaluating sarcoma-specific mortality, mortality due to other causes was considered a competing 
risk and vice versa
c Adjusted for morphology (osteosarcoma/Ewing sarcoma/rhabdomyosarcoma; chondrosarcoma; other or unspecified)
d Adjusted for surgery (yes vs. no), radiotherapy (yes vs. no), and chemotherapy (yes vs. no)
e Proportional hazards assumption was violated for category “Surgery (yes vs. no).” At a follow-up duration of 6.41 years (median), the hazard 
ratio was 0.99 (95% CI: 0.40-2.44) with an increase of a factor 1.58^(years of follow-up after 6.41 years)
f Adjusted for morphology, surgery, radiotherapy, and chemotherapy
g Proportional hazards assumption was violated for category “Surgery (yes vs. no).” At a follow-up duration of 6.41 years (median), the hazard 
ratio was 2.67 (95% CI 0.49–14.61) with an increase of a factor 1.59^ (years of follow-up after 6.41 years)
Overall  mortalitya Sarcoma-specific  mortalityb Mortality other  causesb
HR 95% CI HR 95% CI HR 95% CI
Univariable SMN versus FMN 2.13 1.41–3.22 2.21 1.45–3.37 1.13 0.14–9.74
Multivariable
Model 1: adjustment tumor  characteristicsc
 SMN versus FMN 1.83 1.21–2.78 1.90 1.22–2.96 1.06 0.13–8.47
 Morphology
  Osteosarcoma/rhabdomyosarcoma 1.00 (ref) 1.00 (ref) 1.00 (ref)
  Chondrosarcoma 0.12 0.05–0.29 0.08 0.03–0.26 0.44 0.05–3.96
  Other or unspecified 0.66 0.47–0.92 0.71 0.49–1.01 0.26 0.05–1.38
Model 2: adjustment treatment  characteristicsd
 SMN versus FMN 1.90 1.25–2.90 1.93 1.18–3.18 0.98 0.07–14.54
 Surgery (yes vs. no) 2.40e 0.44–13.05e 0.28 0.18–0.45 0.38 0.03–5.44
 Radiotherapy (yes vs. no) 1.44 1.01–2.06 1.66 1.13–2.44 0.47 0.05–4.23
 Chemotherapy (yes vs. no) 1.88 1.29–2.73 2.12 1.38–3.27 0.44 0.04–5.49
Model 3: adjustment tumor + treatment  characteristicsf
 SMN versus FMN 1.88 1.23–2.87 1.91 1.16–3.13 0.77 0.05–10.97
 Surgery (yes vs. no) 2.67g 0.49–14.61g 0.30 0.19–0.48 0.47 0.04–4.98
 Radiotherapy (yes vs. no) 1.29 0.90–1.85 1.46 1.00–2.13 0.58 0.06–5.18
 Chemotherapy (yes vs. no) 1.68 1.07–2.63 2.13 1.29–3.52 0.13 0.02–0.97
 Morphology
  Osteosarcoma/rhabdomyosarcoma 1.00 (ref) 1.00 (ref) 1.00 (ref)
  Chondrosarcoma 0.26 0.10–0.69 0.23 0.07–0.77 0.14 0.01–1.26
  Other or unspecified 1.08 0.72–1.64 1.33 0.85–2.06 0.10 0.02–0.60
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Table 4  Characteristics of 
patients with female breast 
cancer as a subsequent 
malignant neoplasm (SMN) 
and matched patients with 
female breast cancer as a first 
malignant neoplasm (FMN)
DCOG-LATER 
cohort SMN
(n = 41)
Cancer registry 
FMN
(n = 410)
p value
N % N %
Age at  diagnosisa 1.000
 < 30 years 6 14.6 60 14.6
 30–39 years 23 56.1 230 56.1
 40–49 years 8 19.5 80 19.5
 50 + years 4 9.8 40 9.8
Incidence  yeara 1.000
 1989–1999 7 17.1 70 17.1
 2000–2009 20 48.8 200 48.8
 2010–2014 14 34.2 140 34.2
Morphology breast cancer 0.379
 Ductal 36 87.8 358 87.3
 Lobular 3 7.3 21 5.1
 Mixed ductal/lobular 2 4.9 12 2.9
 Otherb 0 0.0 19 4.6
Stagec 0.499
 I 16 40.0 126 30.9
 II 15 37.5 197 48.3
 III 6 15.0 63 15.4
 IV 3 7.5 22 5.4
 Unknown 1 2
Gradec 0.172
 Well differentiated 2 6.9 37 12.2
 Moderately differentiated 15 51.7 103 33.9
 Poorly differentiated 12 41.4 164 54.0
 Unknown 12 106
ER  statusc 0.202
 Negative 5 16.1 83 28.1
 Positive 26 83.9 212 71.9
 Unknown 10 115
PR  statusc 0.315
 Negative 8 28.6 114 38.9
 Positive 20 71.4 179 61.1
 Unknown 13 117
Her2 receptor  statusc,e 0.803
 Negative 20 76.9 210 79.0
 Positive 6 23.1 56 21.1
 Unknown 15 144
Receptor  statusc 0.393
 Triple negative 2 7.7 55 20.8
 ER and PR negative, Her2 receptor positive 1 3.9 14 5.3
 ER and/or PR positive, Her2 receptor positive 5 19.2 40 15.2
 ER and/or PR positive, Her2 receptor negative 18 69.2 155 58.7
 Unknown 15 146
Surgeryc 0.024
 No 4 9.8 13 3.2
 Mastectomy 26 63.4 202 49.3
 Breast-conserving surgery 11 26.8 193 47.1
 Surgery, type unknown 0 0.0 2 0.5
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Melanoma—comparison of clinical 
and histopathological characteristics
Of 18 eligible patients with subsequent melanoma (mel-
anoma-SMN) after childhood cancer, one patient was 
excluded because of a history of radiotherapy and chemo-
therapy for an intervening ALL diagnosis. We included 17 
melanoma-SMN patients and 170 patients with first primary 
melanoma (melanoma-FMN). More than forty percent of 
melanoma-SMN cases (41.2%) occurred after childhood leu-
kemia and 23.5% of melanoma-SMN cases had prior radio-
therapy to the melanoma region (Supplementary Table 2).
Among patients with melanoma-SMN, 88.2% were diag-
nosed with superficial spreading melanoma, compared to 
68.8% among melanoma-FMN patients. No significant dif-
ferences between melanoma-SMN and melanoma-FMN 
patients were observed for stage distribution and melanoma 
treatment (Table 1).
Melanoma—overall and cause‑specific survival
Median follow-up time was 9.4 years (range 0.9–20.9 years) for 
melanoma-SMN patients and 9.2 years (range 0.4–20.9 years) 
for melanoma-FMN patients. At end of follow-up, 11.8% of 
melanoma-SMN patients were deceased compared to 10.0% 
of melanoma-FMN patients (Table 1). Fifteen-year survival 
exceeded 80% in both patients with melanoma-SMN (82%) 
and melanoma-FMN (87%) (Table 2). Melanoma-specific 
mortality at 15 year since diagnosis was 12.5% for melanoma-
SMN and 10.0% for melanoma-FMN patients. No significant 
differences were observed between melanoma-SMN and 
melanoma-FMN patients in overall survival (multivariable 
CT chemotherapy, ER estrogen receptor, FMN first malignant neoplasm, HT hormonal therapy, PR proges-
terone receptor, RT radiotherapy, SMN subsequent malignant neoplasm
a Matching factors
b Includes seven medullary carcinomas, six mucinous adenocarcinomas, two tubular adenocarcinomas, one 
each of small cell neuroendocrine carcinoma, apocrine adenocarcinoma, medullary carcinoma with lym-
phoid stroma, and metaplastic carcinoma
c Percentages and p values are based on subjects with known information only
d Among breast-SMN cases, two were treated with CT only and 1 each with HT only and no recorded treat-
ment. Among breast-FMN cases, five were treated with CT only, two each with RT + CT, CT + HT, and no 
recorded treatment, and one each with RT + HT and HT only
e Her2 receptor status has been systematically ascertained from September 2005 and patients with a positive 
Her2 receptor status have been treated with Herceptin according to Dutch treatment guidelines since then
Table 4  (continued) DCOG-LATER 
cohort SMN
(n = 41)
Cancer registry 
FMN
(n = 410)
p value
N % N %
Radiotherapy 0.011
 No 20 48.8 116 28.3
 Yes 21 51.2 294 71.7
Chemotherapy 0.022
 No 17 41.5 97 23.7
 Yes 24 58.5 313 76.3
Hormonal therapy 0.870
 No 23 56.1 219 53.4
 Yes 18 43.9 191 46.6
Treatment category 0.011
 No  surgeryd 4 9.8 13 3.2
 Mastectomy, no RT or CT (± HT) 7 17.1 23 5.6
 Mastectomy + RT and/or CT (± HT) 19 46.3 179 43.7
 Breast-conserving surgery, no RT or CT (± HT) 0 0.0 2 0.5
 Breast-conserving surgery + RT and/or CT (± HT) 11 26.8 191 46.6
 Surgery, type unknown 0 0.0 2 0.5
Vital status at end of follow-up 0.325
 Alive 29 70.7 321 78.3
 Deceased 12 29.3 89 21.7
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HR 0.80; 95% CI 0.10–6.21) and melanoma-specific survival 
(univariable HR 0.71; 95% CI 0.10–5.00) (Supplementary 
Table 4).
Discussion
In this study, survival and characteristics of three types of 
solid SMNs from a large cohort of childhood cancer survi-
vors were compared to FMNs of the same type in the gen-
eral population. Survival of patients with sarcomas after 
childhood cancer was poor and significantly worse than 
survival of patients with sarcomas as FMNs. Although we 
observed that breast-SMN patients more often received a 
mastectomy without radiotherapy or chemotherapy com-
pared to breast-FMN patients, survival was not different 
between breast-SMN and breast-FMN patients.
This is one of the few studies to compare SMNs among 
childhood cancer survivors with FMNs occurring in an 
age- and diagnosis-era matched population-based sam-
ple of cancer patients. We found that overall survival was 
worse for sarcoma-SMN patients than for sarcoma-FMN 
patients, both for bone sarcoma and soft-tissue sarcoma. 
This worse survival is in line with results from two regis-
try-based studies in the United States comparing sarcoma-
SMN with sarcoma-FMN patients across patients of all 
ages [14, 23] and with two studies comparing sarcoma-
SMN patients with prior irradiation to sarcoma-FMN 
patients [24, 25]. We observed a considerable shift in type 
of sarcoma seen after childhood cancer as SMN vs. those 
seen as FMN, in particular a shift from Ewing sarcoma and 
dermatofibrosarcoma in the FMN group to osteosarcoma 
in the SMN group. The group of sarcoma-SMN patients 
may harbor more patients with a genetic predisposition 
than sarcoma-FMN patients, especially those patients 
with sarcoma-SMNs occurring after retinoblastoma or 
Li–Fraumeni syndrome-associated tumors [26–28]. The 
stage distribution was not different between the groups 
in our study. Robison et  al. found that sarcoma-SMN 
patients who had received prior radiotherapy to the sar-
coma region seemed to have a more advanced stage than 
sarcoma-FMN patients, although this difference was not 
statistically significant [23]. Similar to what Robison et al. 
reported, grade seemed to be worse among sarcoma-SMN 
patients in our study. However, in both studies, the major-
ity of grades were unknown, so no firm conclusions can 
be drawn [23]. Bjerkehagen et al. showed that the poorer 
prognosis of sarcomas occurring in previous radiation 
fields compared to sporadic sarcomas could be explained 
by more unfavorable factors, such as central tumor site and 
incomplete surgical remission [24]. Treatment modalities 
administered for sarcoma treatment did not differ between 
sarcoma-SMN and sarcoma-FMN patients in our study. 
Although this may indicate that treatment generally was 
not influenced by previous childhood cancer treatment, a 
note of caution is warranted since administration of spe-
cific, effective agents (in particular anthracyclines) may 
Table 5  Regression analyses to ascertain the contribution of tumor 
and treatment characteristics between female breast cancer as a subse-
quent malignant neoplasm (SMN) and female breast cancer as a first 
malignant neoplasm (FMN) with respect to overall and cause-specific 
mortality
CI confidence interval, FMN first malignant neoplasm, HR hazard 
ratio, SMN subsequent malignant neoplasm
a Cox proportional hazards regression analyses including 12 deaths 
among breast-SMN patients and 89 deaths among breast-FMN 
patients
b Competing risk regression analyses. Mortality due to other causes 
was considered a competing risk and vice versa. Univariable HR for 
mortality due to other causes: 10.00 (95% CI 0.64–156.62)
c Adjusted for stage (III/IV vs. I/II). One breast-SMN patient and two 
breast-FMN patients with unknown stage were excluded
d Adjusted for surgery type (mastectomy vs. breast-conserving or type 
unknown), radiotherapy (yes vs. no), and chemotherapy (yes vs. no). 
One breast-SMN patient and two breast-FMN patients without sur-
gery were excluded
e Adjusted for stage, surgery type, radiotherapy, and chemotherapy. 
Two breast-SMN patients and four first-SMN patients were excluded 
because of missing stage or no surgical treatment
Overall 
 mortalitya
Breast cancer-
specific 
 mortalityb
HR 95% CI HR 95% CI
Univariable SMN versus FMN 1.45 0.79–2.65 1.43 0.79–2.59
Multivariable
Model 1: adjustment tumor  characteristicc
 SMN versus FMN 1.32 0.70–2.47 1.30 0.65–2.59
 Stage (III/IV vs. I/II) 4.96 3.30–7.45 5.55 3.62–8.53
Model 2: adjustment treatment  characteristicsd
 SMN versus FMN 1.23 0.61–2.47 1.19 0.61–2.32
 Surgery type (mastectomy vs. 
breast-conserving or type 
unknown)
3.15 1.86–5.34 3.45 1.85–6.41
 Radiotherapy (yes vs. no) 2.14 1.23–3.72 2.35 1.24–4.47
 Chemotherapy (yes vs. no) 0.79 0.47–1.35 0.86 0.47–1.56
Model 3: adjustment tumor + treatment  characteristicse
 SMN versus FMN 1.14 0.54–2.37 1.09 0.49–2.39
 Stage (III/IV vs. I/II) 2.92 1.62–5.26 3.09 1.39–6.85
 Surgery type (mastectomy vs. 
breast-conserving or type 
unknown)
1.90 1.02–3.53 2.03 0.87–4.78
 Radiotherapy (yes vs. no) 1.30 0.66–2.53 1.40 0.54–3.62
 Chemotherapy (yes vs. no) 0.77 0.44–1.33 0.84 0.44–1.60
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differ between the groups. This level of detail is not avail-
able for the cancer registry sample of FMN patients. Also, 
the differences with respect to sarcoma subtypes between 
the groups have somewhat limited the clinical impact of 
our comparisons.
Breast-SMN and breast-FMN patients generally had com-
parable tumor characteristics. No differences between the 
two groups were observed with regard to stage and grade 
distribution, in accordance with two small studies among 
HL survivors [13, 29]. In contrast to our findings, two large 
registry-based studies in AYA cancer survivors did report 
that AYA cancer/HL survivors with breast SMNs were sig-
nificantly more likely to have estrogen- and progestogen-
negative breast cancer compared to breast-FMN patients [16, 
17]. The percentage of triple negative breast cancer in our 
study was lower than that reported in a retrospective case 
series of breast cancer patients with a past history of chest 
radiotherapy (7.7% vs. 29.2%) [30]. An important observa-
tion in our study was the higher proportion of breast-SMN 
patients who had received a mastectomy compared to breast-
FMN patients, in particular the proportion of mastectomy 
without radiotherapy or chemotherapy (17% vs. 6%), as 
reported earlier [10, 13, 16, 17, 29, 31]. Prior chest radio-
therapy treatment for childhood cancer may have limited 
the adjuvant treatment options after breast-conserving sur-
gery and therefore mastectomy may have been the treatment 
of choice. In one breast-SMN patient with a mastectomy 
without radiotherapy or chemotherapy, we found evidence 
that indeed prior childhood cancer radiotherapy led to the 
choice for mastectomy over breast-conserving surgery. We 
found no significant difference in overall survival between 
breast-SMN and breast-FMN patients. However, patients 
with breast-SMN seemed to have slightly higher late cumu-
lative mortality rates (10-year and 15-year) than breast-FMN 
patients, although these differences were not statistically 
significant. Although the high percentage of breast cancer 
as the cause of death among deceased patients is sugges-
tive of breast-SMN patients experiencing more often late 
recurrences/metastases than breast-FMN patients, numbers 
were too small to interpret. Previous registry-based follow-
up studies in Hodgkin lymphoma survivors or in childhood 
and young adult cancer survivors did find a significantly 
increased mortality risk in breast-SMN patients compared 
to breast-FMN patients [14, 16, 17, 29, 31]. Three smaller 
single-institution studies among (Hodgkin) lymphoma sur-
vivors showed mixed results, with one also showing signifi-
cantly worse survival in breast-SMN patients [18], while the 
other study did not find a difference between breast-SMN 
and breast-FMN patients [10, 13]. We observed that the 
large majority of breast-SMN patients died because of the 
breast cancer, in contrast to Milano et al. who found that 
many of the breast-SMN patients after Hodgkin lymphoma 
died of other cancers, heart disease, or other causes [16]. 
The high risks of other fatal late adverse effects among 
patients with Hodgkin lymphoma treated with high dose, 
large volume radiotherapy, and/or high doses of chemother-
apy [32] can probably not be extrapolated to that in a mixed 
cohort of childhood cancer survivors with a large proportion 
of breast cancers in non-irradiated survivors. Compared to 
Hodgkin lymphoma survivors, the group of childhood can-
cer survivors harbors a subpopulation of individuals with 
TP53-related or other genetic predisposition profiles that 
predispose to breast cancer. Therefore, it is possible that 
the related breast tumors are biologically different as well, 
although this a mere hypothesis at this point. Because breast 
cancers in the breast-SMN group were diagnosed at fairly 
young ages, and thus matched breast-FMN group represents 
a sample of young patients, it is likely that the breast-FMN 
group includes several women with a genetic predisposition, 
such as BRCA mutation carriers. Overall survival among 
young individuals with melanoma is very good, with few 
fatalities among SMN and FMN cases alike. Melanoma-
SMN patients harbor no worse prognosis profile vs. mel-
anoma-FMN patients and there are no strong predictors of 
mortality. Keegan et al. did find a slight significantly worse 
overall survival in melanoma-SMN compared to melanoma-
FMN [14]. Previous studies have shown that childhood can-
cer survivors are at increased risk of skin cancers, mainly 
basal cell carcinomas, occurring mainly in skin surface areas 
that had received radiation [33, 34]. Survivors who received 
radiotherapy should be educated to be on alert for local skin 
changes in order to timely seek medical attention for skin 
lesions that may be potentially malignant.
Strengths of our study are the availability of clinical, his-
topathological, and treatment data of solid SMNs from a 
large, nationwide cohort of childhood cancer survivors and 
a matched population-based comparison group of FMNs. 
Furthermore, we were able to not only compare survival, but 
also causes of death, which enabled us to evaluate whether 
survival differences were caused by differences in cancer-
specific mortality or mortality from other causes. A limita-
tion was the relatively small numbers of site-specific SMNs 
included in our study, which may have limited the power 
to detect differences in clinical characteristics and survival 
between the cancer groups. Furthermore, for several tumor 
characteristics (e.g., sarcoma stage and grade and breast 
cancer receptor status information), there was a relatively 
high percentage of the data missing, in particular for cases 
diagnosed in the distant past, when cancer registration (and 
in fact clinical practice) did not include such detail. This 
omission limits impact of these findings.
In conclusion, our exploratory analyses reveal that sur-
vival of sarcoma-SMN patients is poor, with less than one 
in three surviving 15 years after sarcoma-SMN diagnosis, 
and is worse than survival of sarcoma-FMN patients. This 
observation seems partly related to differences in sarcoma 
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subtypes. In our study, breast cancer survival and breast 
tumor characteristics are not different between breast-SMN 
and breast-FMN patients, but treatment differs as breast-
SMN patients receive more often a mastectomy than breast-
FMN patients. Survival of melanoma-SMN is favorable. 
Further studies including more cases should elaborate on 
possible explanations of a worse survival of (soft tissue) 
sarcoma-SMN patients and on treatment strategies and 
underlying deliberations among breast-SMN patients.
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